A Multisite Study of Long-term Remission and Relapse of Type 2 Diabetes Mellitus Following Gastric Bypass

Overview

Journal Obes Surg

Date 2012 Nov 20

PMID 23161525

Citations 181

Authors

David E Arterburn

Andy Bogart

Nancy E Sherwood

Stephen Sidney

Karen J Coleman

Sebastien Haneuse

Patrick J OConnor

Mary Kay Theis

Guilherme M Campos

David McCulloch

Joe Selby

Affiliations

Soon will be listed here.

Abstract

Background: Gastric bypass has profound effects on glycemic control in adults with type 2 diabetes mellitus. The goal of this study was to examine the long-term rates and clinical predictors of diabetes remission and relapse among patients undergoing gastric bypass.

Methods: We conducted a retrospective cohort study of adults with uncontrolled or medication-controlled type 2 diabetes who underwent gastric bypass from 1995 to 2008 in three integrated health care delivery systems in the USA. Remission and relapse events were defined by diabetes medication use and clinical laboratory measures of glycemic control. We identified 4,434 adults with uncontrolled or medication-controlled type 2 diabetes who had gastric bypass.

Results: Overall, 68.2 % (95 % confidence interval [CI], 66 and 70 %) experienced an initial complete diabetes remission within 5 years after surgery. Among these, 35.1 % (95 % CI, 32 and 38 %) redeveloped diabetes within 5 years. The median duration of remission was 8.3 years. Significant predictors of complete remission and relapse were poor preoperative glycemic control, insulin use, and longer diabetes duration. Weight trajectories after surgery were significantly different for never remitters, relapsers, and durable remitters (p = 0.03).

Conclusions: Gastric bypass surgery is associated with durable remission of type 2 diabetes in many but not all severely obese diabetic adults, and about one third experience a relapse within 5 years of initial remission. More research is needed to understand the mechanisms of diabetes relapse, the optimal timing of surgery in effecting a durable remission, and the relationship between remission duration and incident microvascular and macrovascular events.

Citing Articles

SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.

Wander P, Lowy E, Korpak A, Beste L, Kahn S, Boyko E PLoS One. 2025; 20(2):e0317348.

PMID: 39970150 PMC: 11838867. DOI: 10.1371/journal.pone.0317348.

Integrated Insights into Metabolic and Bariatric Surgery: Improving Life Quality and Reducing Mortality in Obesity.

Marin R, Radu A, Negru P, Radu A, Negru D, Aron R Medicina (Kaunas). 2025; 61(1).

PMID: 39858996 PMC: 11767230. DOI: 10.3390/medicina61010014.

Clinical outcomes of roux-en-Y gastric bypass versus medical therapy in type 2 diabetes mellitus: a systematic review and meta-analysis.

Gul D, Khan A, Butt M, Suheb M, Sartaj S, Chabria S J Diabetes Metab Disord. 2025; 24(1):43.

PMID: 39801690 PMC: 11723861. DOI: 10.1007/s40200-024-01526-z.

Bariatric surgery for treatment of morbid obesity in adults.

Park K, Jun K Korean J Intern Med. 2025; 40(1):24-39.

PMID: 39778524 PMC: 11725483. DOI: 10.3904/kjim.2024.219.

Diabetes Remission After Bariatric Surgery: A 10-Year Follow-Up Study.

Meira I, Menino J, Ferreira P, Leite A, Goncalves J, Ferreira H Obes Surg. 2024; 35(1):161-169.

PMID: 39715944 PMC: 11717815. DOI: 10.1007/s11695-024-07592-9.

References

Schauer D, Arterburn D, Livingston E, Fischer D, Eckman M . Decision modeling to estimate the impact of gastric bypass surgery on life expectancy for the treatment of morbid obesity. Arch Surg. 2010; 145(1):57-62. PMC: 2862372. DOI: 10.1001/archsurg.2009.240. View

. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003; 290(16):2159-67. PMC: 2622725. DOI: 10.1001/jama.290.16.2159. View

Cleary P, Orchard T, Genuth S, Wong N, Detrano R, Backlund J . The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006; 55(12):3556-65. PMC: 2701297. DOI: 10.2337/db06-0653. View

Pournaras D, Aasheim E, Sovik T, Andrews R, Mahon D, Welbourn R . Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg. 2011; 99(1):100-3. DOI: 10.1002/bjs.7704. View

Nannipieri M, Mari A, Anselmino M, Baldi S, Barsotti E, Guarino D . The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab. 2011; 96(9):E1372-9. DOI: 10.1210/jc.2011-0446. View

Thaler J, Cummings D . Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009; 150(6):2518-25. DOI: 10.1210/en.2009-0367. View

Arterburn D, Schauer D, Wise R, Gersin K, Fischer D, Selwyn Jr C . Change in predicted 10-year cardiovascular risk following laparoscopic Roux-en-Y gastric bypass surgery. Obes Surg. 2008; 19(2):184-189. DOI: 10.1007/s11695-008-9534-7. View

Bantle J, Wylie-Rosett J, Albright A, Apovian C, Clark N, Franz M . Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008; 31 Suppl 1:S61-78. DOI: 10.2337/dc08-S061. View

Vetter M, Cardillo S, Rickels M, Iqbal N . Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009; 150(2):94-103. DOI: 10.7326/0003-4819-150-2-200901200-00007. View

10.

Schauer P, Kashyap S, Wolski K, Brethauer S, Kirwan J, Pothier C . Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012; 366(17):1567-76. PMC: 3372918. DOI: 10.1056/NEJMoa1200225. View

11.

Renard E . Bariatric surgery in patients with late-stage type 2 diabetes: expected beneficial effects on risk ratio and outcomes. Diabetes Metab. 2010; 35(6 Pt 2):564-8. DOI: 10.1016/S1262-3636(09)73467-6. View

12.

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

13.

Campos G, Rabl C, Mulligan K, Posselt A, Rogers S, Westphalen A . Factors associated with weight loss after gastric bypass. Arch Surg. 2008; 143(9):877-883. PMC: 2747804. DOI: 10.1001/archsurg.143.9.877. View

14.

Kadera B, Lum K, Grant J, Pryor A, Portenier D, DeMaria E . Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis. 2009; 5(3):305-9. DOI: 10.1016/j.soard.2009.02.007. View

15.

. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7):1327-34. PMC: 2699715. DOI: 10.2337/dc09-9033. View

16.

Cummings D . Metabolic surgery for type 2 diabetes. Nat Med. 2012; 18(5):656-8. DOI: 10.1038/nm.2773. View

17.

Dixon J, OBrien P, Playfair J, Chapman L, Schachter L, Skinner S . Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008; 299(3):316-23. DOI: 10.1001/jama.299.3.316. View

18.

Pories W, MacDonald Jr K, MORGAN E, Sinha M, Dohm G, Swanson M . Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr. 1992; 55(2 Suppl):582S-585S. DOI: 10.1093/ajcn/55.2.582s. View

19.

DiGiorgi M, Rosen D, Choi J, Milone L, Schrope B, Olivero-Rivera L . Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis. 2010; 6(3):249-53. DOI: 10.1016/j.soard.2009.09.019. View

20.

Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S . How do we define cure of diabetes?. Diabetes Care. 2009; 32(11):2133-5. PMC: 2768219. DOI: 10.2337/dc09-9036. View